TamaBio has completed capital increase through third-party allotment (Round B).
An Advanced Research Presentation on the Biocompatibility and Tissue Regeneration Ability of DuraBeam®, the artificial dura mater, will be held at JSAN2025 (The 18th Annual Meeting of the Japanese Society of Aesthetic Neurosurgery, April 18th (Fri) – 19th (Sat), 2025).
Touch samples of the synthetic artificial dura mater “DuraBeam®” will be exhibited at STROKE2025 (50th Annual Meeting of the Japan Stroke Society; Thursday, March 6th to Saturday, March 8th, 2025).
“DuraBeam®” was exhibited at the 48th Japanese Society of Neurotraumatology (Friday, February 21st to Saturday, February 22nd, 2025).
“PeriBeam®” was exhibited at the 55th Annual Meeting of the Japanese Society for Cardiovascular Surgery (Thursday, February 20th to Saturday, February 22nd, 2025).
Our Medical Devices Development Pipeline has been updated.
The number of clinical uses of “DuraBeam®”, the artificial dura mater, has exceeded 3,000 cases.
TamaBio has obtained patents for Regenerative Medical Devices : Nerve Damage Repair Sheet, Brain Tissue Damage Repair Sheet and Spinal Cord Injury Repair Sheet.
The joint research period with Tohoku University has been extended.
We will be a sponsor and exhibit at the The 34th Conference on Neurosurgical Techniques and Tools (CNTT2025; Osaka International Convention Center, April 18th (Fri) to 19th (Sat), 2025).
